Drug profile · INN
fedratinib hydrochloride
INREBIC
fedratinib hydrochloride (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — fedratinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fedratinib hydrochloride (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK2 inhibitor
Primary target: Tyrosine-protein kinase JAK2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is fedratinib hydrochloride?
fedratinib hydrochloride (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fedratinib hydrochloride?
INREBIC is a marketed brand name for fedratinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fedratinib hydrochloride?
fedratinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.